Payment overview · 2025
General Payments
$430.10
17 reported records · 12 companies
Healthcare provider profile · identity verified
Rakesh Chander Gupta, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · SAN JACINTO, CA · NPI 1871574996
Verified facts
What the public records show
CMS Open Payments records show Rakesh Chander Gupta, MD received $430.10 in general payments during 2025 across 17 reported records.
Medtronic, Inc. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$69.00 | 16.0% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $59.15 | 13.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.43 | 11.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.53 | 11.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.82 | 9.0% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $34.78 | 8.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.63 | 6.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.00 | 6.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.92 | 5.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.48 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.84 | 3.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.52 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $430.10 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $59.15 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $58.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.43 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.53 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1142 | 313 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 774 | 177 |
| Montelukast Sodium | Montelukast Sodium | 366 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 94 |
| Spiriva Respimat | Tiotropium Bromide | 206 | 43 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 189 | 51 |
| Breo Ellipta | Fluticasone/Vilanterol | 183 | 34 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 180 | 45 |
| Trazodone Hcl | Trazodone Hcl | 140 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 130 | 27 |
| Incruse Ellipta | Umeclidinium Bromide | 124 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 102 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 29 |
| Azithromycin | Azithromycin | 94 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 86 | 19 |
| Qvar Redihaler | Beclomethasone Dipropionate | 86 | 18 |
| Azelastine Hcl | Azelastine Hcl | 85 | 27 |
| Furosemide | Furosemide | 80 | 19 |
| Methylprednisolone | Methylprednisolone | 79 | 44 |
| Prednisone | Prednisone | 71 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 67 | 16 |
| Losartan Potassium | Losartan Potassium | 67 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 66 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 12 |
| Potassium Chloride | Potassium Chloride | 60 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 17 |
| Famotidine | Famotidine | 53 | 11 |
| Lisinopril | Lisinopril | 49 | 13 |
| Simvastatin | Simvastatin | 47 | suppressed |
| Gabapentin | Gabapentin | 46 | 13 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 45 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 11 |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Omeprazole | Omeprazole | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 32 | 12 |
| Linzess | Linaclotide | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terbutaline Sulfate | Terbutaline Sulfate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $430.10 · 17 records | Medtronic, Inc. | ACCRUFER, BREZTRI, CAPLYTA, DUPIXENT, ENTRESTO, Fetroja, IBSRELA, LEQVIO, MOUNJARO, VRAYLAR, YUPELRI, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error